Alcidion Acquires Kyra Flow Products in $3M Deal Adding 33 Customers

Strategic Expansion in Patient Flow Solutions

Alcidion Group Limited (ASX:ALC) has taken a decisive step to deepen its hold on the Australian patient flow market by acquiring the Kyra flow products from Telstra Health for an upfront cash consideration of $3 million, with an additional earn-out of up to $1 million. This move not only broadens Alcidion’s customer base by approximately 33 long-standing clients but also significantly extends its footprint into Queensland, Victoria, Western Australia, and Tasmania, regions where Kyra’s solutions are already embedded in hospital systems.

The Kyra suite, comprising Patient Flow Manager, Queue Manager, and Kyra IQ, addresses critical operational challenges in managing inpatient and outpatient flows, real-time data access, and administrative efficiencies. Alcidion’s CEO Kate Quirke emphasised that the acquisition aligns tightly with the company’s strategy to build a scalable, recurring revenue-driven health technology platform, leveraging the established customer relationships and product capabilities of Kyra.

Financial Profile and Earnings Impact

Forecast revenue for the Kyra assets in FY26 stands at $3.7 million with an underlying EBITDA of approximately $1.1 million, of which over 90% is recurring revenue from support and maintenance contracts. The acquisition is expected to be earnings accretive from completion, anticipated by the end of June 2026, at an implied EBITDA multiple of 2.7 times based on upfront payment. Alcidion will fund the transaction from its healthy cash reserves, which stood at $15.1 million as of March 31, 2026, with no debt on the balance sheet.

This deal follows Alcidion’s recent strong financial momentum, including a reported 44% revenue surge and a turnaround to profitability earlier this year, as well as ongoing contract expansions in Australia and the UK. The Kyra acquisition complements its flagship Miya Precision platform and adds to its growing portfolio of patient flow and clinical decision support tools, reinforcing its position as a leading healthcare IT provider across multiple markets 44% revenue surge and profit turnaround.

Customer Base and Market Reach

Notably, only two of Kyra’s 33 customers overlap with Alcidion’s existing client base, presenting a meaningful opportunity to cross-sell and deepen engagement. The Kyra products have entrenched relationships, with the top 10 customers averaging a decade-long tenure, underscoring the critical and embedded nature of these solutions in hospital operations. The acquisition also strengthens Alcidion’s presence in Queensland, where it recently secured a five-year contract with Gold Coast Health, a Kyra customer, potentially opening avenues for integrated service offerings.

Telstra Health’s Managing Director Elizabeth Koff highlighted that the divestment aligns with Telstra’s strategic focus on building a care intelligence ecosystem spanning primary, community, and aged care sectors, while entrusting Kyra’s hospital-centric solutions to a specialist operator. The transition aims to maintain seamless service continuity for customers, leveraging Alcidion’s expertise and infrastructure to evolve the Kyra suite.

Integration and Future Opportunities

Alcidion’s acquisition strategy has been marked by targeted deals that build on its core competencies and expand its recurring revenue base. The Kyra flow products acquisition is expected to create future synergies, particularly in enhancing the value proposition of its Miya Precision platform and expanding digital health infrastructure insights. Maintaining long-term customer relationships and delivering uninterrupted support will be critical to realising these benefits.

With the healthcare sector’s increasing focus on optimising patient flow amid rising admission rates and an ageing population, the demand for validated digital solutions remains strong. Alcidion’s move to consolidate its market position through this acquisition positions it to capitalise on these structural trends, while also navigating competitive pressures in the healthcare IT landscape Q3 cashflow and contract expansions.